Adding functionality with additive manufacturing : fabrication of titanium-based antibiotic eluting implants by Cox, Sophie C et al.
©2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-
NoDerivatives 4.0 International http://creativecommons.org/about/downloads  
 
 
  
Adding functionality with additive manufacturing: Fabrication of titanium-
based antibiotic eluting implants 
Sophie C. Cox1, Parastoo Jamshidi2, Neil M. Eisenstein1, Mark A. Webber3, Hany 
Hassanin2, Moataz Attallah2, Duncan E.T. Shepherd4, Owen Addison5, Liam M. 
Grover1 
1School of Chemical Engineering, University of Birmingham, Edgbaston, B15 2TT, UK 
2School of Materials and Metallurgy, University of Birmingham, Edgbaston, B15 2TT, UK 
3School of Biosciences University of Birmingham, Edgbaston, B15 2TT, UK 
4Department of Mechanical Engineering, School of Engineering, University of Birmingham, 
Edgbaston, B15 2TT, UK 
5School of Dentistry, University of Birmingham, Edgbaston, B15 2TT, UK 
 
  
Abstract 
Additive manufacturing technologies have been utilised in healthcare to create 
patient-specific implants. This study demonstrates the potential to add new implant 
functionality by further exploiting the design flexibility of these technologies. Selective 
laser melting was used to manufacture titanium-based (Ti-6Al-4V) implants 
containing a reservoir. Pore channels, connecting the implant surface to the 
reservoir, were incorporated to facilitate antibiotic delivery. An injectable brushite, 
calciumphosphate cement, was formulated as a carrier vehicle for gentamicin. 
Incorporation of the antibiotic significantly (p=0.01) improved the compressive 
strength (5.8± 0.7 MPa) of the cement compared to non-antibiotic samples. The 
controlled release of gentamicin sulphate from the calcium phosphate cement 
injected into the implant reservoir was demonstrated in short term elution studies 
using ultraviolet visible spectroscopy. Orientation of the implant pore channels were 
shown, using micro-computed tomography, to impact design reproducibility and the 
back-pressure generated during cement injection which ultimately altered porosity. 
The amount of antibiotic released from all implant designs over a 6 hour period 
(b28% of the total amount) were found to exceed the minimum inhibitory 
concentrations of Staphylococcus aureus (16 μg/mL) and Staphylococcus 
epidermidis (1 μg/mL); two bacterial species commonly associated with 
periprosthetic infections. Antibacterial efficacy was confirmed against both bacterial 
cultures using an agar diffusion assay. Interestingly, pore channel orientation was 
shown to influence the directionality of inhibition zones. Promisingly, this work 
demonstrates the potential to additively manufacture a titanium-based antibiotic 
eluting implant, which is an attractive alternative to current treatment strategies of 
periprosthetic infections.   
 
 
  
1. Introduction 
Generally, total joint arthroplasty is a successful procedure that restores function and 
improves patient quality of life. Despite the introduction of standardised strategies, 
such as laminar flow clean air operating rooms and pre-operative antibiotics, 
periprosthetic infection still occurs in approximately 1–2% of patients following a total 
joint arthroplasty procedure [1] and [2]. When periprosthetic infections do occur they 
can lead to a need for rescue or revision surgery, and ultimately device failure. As 
such, implant infection represents one of the most costly complications in 
orthopaedic surgery. 
Clinical procedures for the treatment of periprosthetic infection, include irrigation and 
debridement with component retention [3], as well as one- and two-stage exchange 
arthroplasty [4] and [5]. Two-stage exchange arthroplasty involves the implantation 
of an interim antibiotic-loaded component after removal of the original components. 
Commonly, antibiotic-loaded polymethylmethacrylate (PMMA) is used in the form of 
beads or cast into a mould and implanted [6], [7] and [8]. PMMA cements set via an 
exothermic reaction, reaching temperatures between 70 and 120 °C [9]. This thermal 
behaviour limits the antibiotics PMMA may be combined with and it has been shown 
to result in tissue necrosis [10] and [11]. Other disadvantages include chemical 
necrosis due to leakage of unreacted monomer, shrinkage during polymerisation, 
and its inability to be resorbed [12]. The interim period in a two-stage exchange 
arthroplasty may range from 6 to 12 weeks depending on individual surgeon 
decision, and evidence of infection clearance and healing [13]. During this time, 
patients may be encouraged to walk with partial weight-bearing [14]. Complications 
associated with the interim period include sacral pressure sores and fractures on re-
implantation [14]. Furthermore, increased morbidity from two-stage compared to 
one-stage exchange has been reported [15]. Some of these complications may be 
associated with the inactivity of the patient between procedures in a two-stage 
exchange arthroplasty. 
Current orthopaedic implants are manufactured from stainless steels, cobalt 
chromium molybdenum alloys, and titanium alloys using traditional manufacturing 
methods (e.g. machining, forging, and investment casting) [16]. These processes 
have been optimised over a number of decades resulting in implants that can 
withstand long-term cyclic loading. In recent years, the use of additive manufacturing 
(AM) techniques in medicine has gained much attention [17], [18], [19], [20] and [21]. 
Generally, AM techniques use a layer-by-layer approach to build parts from 
computer aided design (CAD) models. In comparison to conventional methods, this 
approach enables material wastage to be reduced and greater geometrical design 
freedom. 
Selective laser melting (SLM) is an AM technology that may be used to manufacture 
metal components [22], [23], [24] and [25]. During this process, a focused laser 
beam is used to selectively heat a bed of metallic powder above the materials 
melting point causing the particles to melt and fuse together. After completion of 
each two-dimensional (2D) layer, the build platform is lowered by a pre-set thickness 
and the coating blade spreads a fresh layer of powder on top. This process is 
repeated until the full 3-dimensional (3D) geometry has been built. All processing is 
conducted in a chamber flooded with inert gas, usually nitrogen or argon to minimise 
oxygen-content. 
To date, bone prostheses manufactured via AM technologies have primarily been 
employed clinically in relatively low load-bearing areas, such as the Food and Drug 
Administration approved OsteoFab® (Oxford Performance Materials); a patient 
specific polymer based cranial device. The introduction of metallic AM implants in 
high fatigue applications, such as permanent components of hip or knee implants, 
has been hindered by their rough surface features acting as fatigue crack initiation 
sites. Shorter fatigue life has been previously demonstrated through a comparative 
fatigue study of additively manufactured and equivalent rolled Ti-6Al-4V dental 
implants [26]. 
In the context of the challenges discussed above, the use of a device that would 
enable patients to fully weight-bear whilst eluting antibiotics during the interim period 
of a two-stage exchange arthroplasty is an attractive concept. This could be 
achieved by manufacturing an implant that is mechanically robust enough to 
withstand the patient's weight but also contains a reservoir that could be filled with an 
injectable antibiotic eluting biomaterial. To maintain and tailor structural properties a 
honeycomb type lattice could be introduced within the reservoir region. The 
geometrical freedom possible from AM technologies would facilitate the manufacture 
of such an intricate internal architecture, which would not be possible via traditional 
methods. Furthermore, if the device was used only in the interim period this would 
circumvent any long-term fatigue issues. Design of a metallic device that satisfies 
mechanical criteria would remove this demand from the antibiotic eluting material 
allowing for selection to be solely focused on desired therapeutic properties. This 
strategy in comparison to the use of antibiotic-loaded PMMA, which must fulfil both 
mechanical and therapeutic demands, may present advantages. 
This paper presents a preliminary study to assess the feasibility of utilising SLM to 
manufacture an antibiotic eluting implant. Simplified cylindrical implants were 
designed to incorporate a reservoir connected to the surface extremities via a series 
of channels. A calcium phosphate cement, brushite, was selected as an antibiotic 
carrier and injected into the AM metallic implant. This material was chosen since, in 
comparison to PMMA, it sets at lower temperatures and is highly resorbable at 
physiological conditions [27]. The influence of pore orientation (horizontal, vertical, 
45° incline) on the release profile of gentamicin sulphate from the implant was 
assessed. Antibacterial efficacy was demonstrated against two bacterial species 
commonly associated with periprosthetic infections. Overall, this work highlights the 
potential to add further value and functionality to orthopaedic implants by exploiting 
the advantages that AM technologies bring to manufacturing. 
2. Materials and Methods 
2.1 Brushite cement formulation 
Dicalcium phosphate dihydrate (CaHPO4·2H2O) (DCPD), otherwise known as 
brushite, is a calcium phosphate phase that is several orders of magnitude more 
soluble than hydroxyapatite in physiological conditions [27]. Clinically, cements with 
a high injectability and a setting time between 5 and 15 min are desirable as this 
allows time for prosthesis implantation and adjustment but does not prolong the 
operation excessively. 
A brushite cement formulation with an injectability of > 80% through a 15G (1.829 
mm) needle and a setting time of approximately 12 min was preselected for this 
study (data not shown). The cement was formulated using β-tricalcium phosphate (β-
Ca3(PO4)2) (β-TCP) synthesised using a previously reported method [28]. β-TCP 
and monocalcium phosphate monohydrate (Ca(H2PO4)2⋅H2O, Innophos, USA) 
(MCPM) powders were dry mixed in stoichiometric ratios (Eq. (1)) for 30 s using a 
spatula. The powder components were then mixed with deionised water at a 2:1 
powder-to-liquid ratio (PLR) for 30 s to form a workable paste. 
β-Ca3(PO4)2 + Ca(H2PO4)2H2O + 7H2O  4CaHPO42H2O         (1) 
Antibiotic loaded brushite cements were prepared by dissolving gentamicin sulphate 
(Sigma Aldrich, UK) at a concentration of 100 mg/mL into deionised water prior to 
mixing with the powder components giving a final concentration of 50 mg per 1g of 
cement.  
2.2 Manufacture of cement cylinders 
Prepared cement pastes (Section 2.1) were formed into cylinders (diameter = 6 mm; 
height = 12 mm) by either casting or injecting into a PTFE split mould. Cast cylinders 
were made by pouring cement paste into the mould positioned on a Denstar-500 
powered vibrating platform (Denstar, Korea). Injected cylinders were formed by 
loading cement pastes into a 5 mL syringe with 15G (1.829 mm internal diameter) 
needle after mixing and injecting into the split mould. Both cast and injected cement 
cylinders were left to set in the mould for 1 h in an incubator at 37 °C, demoulded, 
and stored in an incubator at 37 °C until use. Injected cement cylinders were 
manufactured so as to simulate the intended clinical delivery method and this was 
compared with cast versions (n = 10) as this is the typical process used in the 
literature [29] and [30]. 
2.3 Additive manufacture of implant models 
Implant models (Fig. 1a) were fabricated from Ti-6Al-4V gas atomised powder (TLS 
Technik, Germany) sized 20–50 μm using a M2 Cusing® SLM system (Concept 
Laser, Germany), which employs an Nd:YAG laser with a wavelength of 1075 nm, 
spot size of 60 μm and a maximum laser output power of 400 W. The process 
parameters were optimised to reduce residual porosity and achieve the designed 
hole geometry for elution of gentamicin. The parameters used were 150 W laser 
power, 1750 mm/s scanning speed, 20 μm slice thickness, and hatch spacing of 75 
μm. Support structures were built between the substrate base and each individual 
implant to provide stability during the build. Manufacture was conducted in a 
chamber flooded with argon gas to minimise oxygen pick-up to < 0.1%. 
 
Figure 1: Implant models a) CAD schematics and photomicrographs of Ti-6Al-4V implants 
manufactured via selective laser melting with 1 mm horizontal, inclined, and vertical pore 
orientations, and b) re-engineered demonstration hip prostheses of varying transparency 
designed using Solidworks. 
 
2.4 Loading implants with cement paste 
Prepared cement pastes were loaded into 5 mL syringes attached to a 15G needle 
and injected into the single 2 mm diameter hole at the top of all cylindrical designs 
(Fig. 1). 
2.5 Characterisation of materials 
2.5.1 Cement composition 
X-ray diffraction (XRD) analysis of set cements was performed on a Bruker D8 
Advance Diffractometer (ASX Gmbh, Bruker, Germany). Cement cylinders were 
prepared (Section 2.1) and ground into a fine powder using a pestle and mortar. 
Approximately 500 mg of the powder was distributed over a 10 mm diameter circular 
area of Scotch tape (3 M, UK) and attached to the sample holder. Data were 
collected over a 2θ range of 5–60° with a step size of 0.02° and a count time of 0.5 s 
per step. Diffraction patterns were matched with the International Centre for 
Diffraction Data (ICDD) standards using EVA software (version 3.1, Bruker). 
 2.5.2 Cement morphology 
Cement segments were attached to aluminium stubs using conducting silver paint 
and sputter coated with gold in an argon purged chamber for 120 s. Micrographs of 
cement surfaces were obtained using an EVO MA 10 scanning electron microscope 
(Carl Zeiss Ltd, UK).   
2.5.3 Cement compressive strength 
Geometrical measurements of nominally identical cement cylinders were taken using 
digital callipers and the mass of each specimen was measured. Each cylinder was 
mounted on the lower anvil of a Z030 universal testing machine (Zwick, UK) with its 
long axis perpendicular to the surface of the anvil. A minimum of 10 samples were 
compressed to failure at a constant rate of 1 mm/min. The ultimate compressive 
strength (σ) was calculated from the maximum load recorded throughout each test 
(Eq. (2)). Young's modulus (E) was determined from the linear region of the stress 
strain graph using linear regression (Eq. (3)). 
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where 𝐹 is force, 𝐴 original area, 𝑙0 original length of specimen, 𝑙 compressed length 
of specimen, and 𝜀 specimen strain. 
2.5.4 Cement density 
The apparent density of cement samples was calculated from geometrical and mass 
measurements made prior to the mechanical testing. After compression testing, 
cement fragments were collected and used to determine the true density using a 
helium pycnometer (Accupyc 1330, Micromeritics, UK). The sample chamber was 
purged with helium five times before five consecutive measurements of volume were 
performed. For each sample set, the true density of three different cement cylinders 
was determined so that reported values were a mean of 15 measurements. Relative 
porosity was calculated from the values of true and apparent density.  
2.5.5 Micro-computer tomography 
Cement cylinders were scanned using a Skyscan1172 micro-computed tomography 
(micro-CT) system (Bruker, Belgium) with 80 kV maximum X-ray energy, 8 W beam 
power, 570 ms exposure per projection, 0.5 mm aluminium filter, and 4.87 μm pixel 
size. Empty and filled SLM implant models were also scanned with 80 kV maximum 
X-ray energy, 8 W beam power, 2000 ms exposure per projection, aluminium and 
copper filter, and 5.95 μm pixel size. Reconstructed data were visualised in 2D and 
3D using DataViewer (version 1.5.1.2, Bruker) and CTVox (version 3.0, Bruker) 
software, respectively.  
A porosity analysis of cast, injected, and injected gentamicin-loaded cement 
cylinders was conducted using CTAn (version 1.15.4.0, Bruker) software. Briefly, a 
circle was fitted to the external edges of the cement cylinder to create a region of 
interest (ROI). This ROI was interpolated across 100 slices positioned in the middle 
of the longitudinal axis (y-axis) of the sample volume to create a volume of interest 
(VOI). A global thresholding was applied to create a binary image, which was then 
filtered to remove noise, and a ROI shrink wrap function used to define the sample 
extremities. 3D analysis was run over this VOI to determine total, open, and closed 
porosity as well as the size distribution of open and closed pores. Micro-CT values of 
porosity were compared with those obtained from true density measurements. β-
TCP content of the cement VOI was calculated by conducting 3D analysis of 
greyscale values defined as unreacted phase and compared with the total solid 
volume calculated for the same VOI. 
To validate CAD implant model geometries, measurements of the pores were 
obtained from binary micro-CT slice data and compared with designed dimensions 
(1000 μm). Four measurements of each pore were taken so that mean values for 
each design were calculated from a total of 16 measurements. 
2.5.6 Release of gentamicin 
Gentamicin release studies were conducted by immersing cement cylinders and 
implant models containing injected cement in 10 mL of phosphate buffered saline 
(PBS) stirred at 100 rpm and incubated at 37 °C. Every 30 min up to 3 h and every 
hour from 3 to 6 h, 10 mL was withdrawn from each sample (n = 3) and assayed for 
gentamicin by measuring the absorbance at 246 nm using a CE 7500 UV–Vis 
spectrophotometer (Cecil Instruments, UK). Samples of cement without gentamicin 
were also assayed and the blank subtracted. Antibiotic concentration in the elution 
media was determined using a calibration curve of absorbance values for known 
concentrations of gentamicin dissolved in PBS. 
2.5.7 Bacterial inhibition 
The minimum inhibitory concentration (MIC) of gentamicin sulphate against 
Staphylococcus aureus (NCTC 8532) and Staphylococcus epidermidis (NCTC 
11047) was determined using a standard broth MIC assay [31]. 
In addition, antibacterial efficacy of injected cement cylinders (with and without 
gentamicin) and implant models filled with gentamicin loaded cement was 
determined using an agar diffusion assay. Briefly, overnight broth cultures of S. 
aureus and S. epidermidis were diluted to an optical density of 0.06 (at 600 nm) and 
these dilutions were then used to inoculate the surface of nutrient agar plates. Holes 
of the approximate diameter of the cement cylinders or the implants were bored into 
the agar. Three samples were placed in each agar plate and incubated at 37 °C 
overnight to allow semi confluent lawns of growth. After this time the diameter of any 
inhibition zones were measured and images taken. 
2.6 Statistics 
Results are presented as mean values ± standard deviation. Two tail, two sample t-
tests were conducted in Microsoft Excel to determine any statistical significance 
between measured properties of different cement formulations. P values < 0.05 were 
deemed significant. A single factor analysis of variance (ANOVA) test was conducted 
on inhibition zone diameter measurements between the three groups of different 
pore channel orientations (Fig. 7). 
3.0 Results 
3.1 Characterisation of calcium phosphate cements 
XRD patterns of cast, injected, and injected gentamicin loaded cements were 
primarily matched to ICDD standards for brushite (PDF 00-009-0077) (Fig. 2a). An 
isolated peak at 27.77° was also detected in all samples, which was associated to 
residual β-TCP (PDF 00-009-0169). This peak was notably more intense in the 
antibiotic loaded cement compared with both blank formulations. Micrographs of 
cement fracture surfaces revealed two distinct particle morphologies; larger 
heterogeneous and finer plate-like crystals were observed in blank and gentamicin 
loaded injected cements (Fig. 2b). These observations are consistent with XRD data 
that identified two phases; the larger heterogeneous particles were consistent with 
micrographs of precursor β-TCP powder (data not shown) and brushite is known to 
exhibit a plate-like morphology.  
 
 
Figure 2: Characterisation of brushite cement samples a) XRD data of cast, injected, and 
gentamicin loaded cements illustrating matching to DCPD (▲ 00-009-0077) and β-TCP (♦ 
00-009-0169) reference patterns, and b) micrographs illustrating residual β-TCP particles 
(blue circles) in formulated cements fragments (i without gentamicin and ii with gentamicin) 
and typical morphology of plate-like brushite crystals (iii without gentamicin and iv with 
gentamicin). 
 
No significant variation in compressive strength (p = 0.92) or true density (p = 0.14) 
was observed between cast and injected cement cylinders (Table 1). The addition of 
gentamicin was shown to significantly increase the maximum compressive strength 
compared with injected (p = 0.01) samples. Addition of the antibiotic was, however, 
not found to significantly alter the true density (p = 0.35) or relative porosity (p = 
0.72) compared to injected samples without gentamicin. 
 
Table 1: Comparison of mechanical testing and helium pycnometer results for brushite 
cement formulations. Results presented as mean ± standard deviation 
Cement Formulation Cast Injected Injected with gentamicin 
Compressive Strength (MPa) 4.50 ± 0.59 4.54 ± 1.00 5.77 ± 0.69 
Young’s Modulus (GPa) 0.26 ± 0.13 0.17 ± 0.06 0.23 ± 0.05 
Apparent Density (g/cm3) 1.58 ± 0.01 1.66 ± 0.02 1.59 ± 0.10 
True Density (g/cm3) 2.13 ± 0.03 2.33 ± 0.16 2.17 ± 0.22 
Relative Porosity (%) 25.59 ± 1.24 28.77 ± 5.03 26.38 ± 9.44 
 
Micro-CT data was consistent with XRD analysis since it revealed the presence of 
two phases, distinguished by different grey scale values, within all cement cylinders 
(Fig. 3). The pixels associated with higher grey scale values (i.e. whiter) may be 
associated with β-TCP particles since it is a higher density than brushite. Unreacted 
β-TCP particles were heterogeneously dispersed throughout all samples as 
demonstrated in grey scale images (Fig. 3). It is important to note that a good 
agreement was observed between grey scale and binary micro-CT data; this 
demonstrates that appropriate thresholding techniques were used prior to 3D 
analysis. 
3D analysis was used to calculate the porosity (open and closed) and β-TCP content 
of cement formulations (Fig. 3). The porosity within all samples was predominantly 
open (> 90% of the total porosity), i.e. connected to the extremity of the cement 
cylinder. Closed pores within samples were generally distributed at the extremities of 
the cement cylinders (Fig. 3) and > 85% were < 24.4 μm (Table 2). Manufacturing 
via injection was found to increase the cement porosity and β-TCP content 
compared with casting (Fig. 3). Addition of gentamicin was shown to increase β-TCP 
content compared with unloaded injected cylinders. Notably a higher volume of open 
and closed pores within cast cements (35, 16%) were > 24.4 μm compared with 
injected without (16, 6%) and with gentamicin (8, 0.5%) samples (Table 2). 
 
Figure 3: Images illustrating the 2D solid and pore structure of cement cylinders, notably the 
presence of two distinguishable phases can be observed in grey scale cement micrographs. 
*Calculated as a % of the total solid volume. 
 
 
  
Table 2: Pore size range of open and closed porosity within cement formulations calculated 
from micro-CT data 
Pore Size 
Range (μm) 
Volume Within Range (%) 
Open Porosity Closed Porosity 
Cast Injected 
Injected 
with 
gentamicin 
Cast Injected 
Injected 
with 
gentamicin 
4.9 - <14.6 16.7 31.2 38.8 39.0 59.6 87.8 
14.6 - <24.4 48.3 52.9 53.5 46.9 34.7 11.7 
24.4 - <34.1 23.9 12.5 5.87 11.1 5.07 0.41 
34.1 - <43.8 8.15 2.52 0.77 2.68 0.60 0.08 
43.8 - <53.6 1.56 0.35 0.30 0.35 0 0 
53.6 - <63.3 0.29 0.08 0.21 0.04 0 0 
63.3 - < 200 1.14 0.47 0.55 0 0 0 
 
Micro-CT was used to reveal the morphology, size, and surface topography of SLM 
parts before being filled with cement (Fig. 4). All orientations of hole designs were 
found to penetrate into the reservoir region (Fig. 4a) and the internal hole geometry 
was found to exhibit a similar degree of surface roughness to the extremities of the 
parts (Fig. 4b). Average measurements of hole size (Fig. 4c) revealed that the 
vertical orientation adhered most closely to the CAD design of 1000 μm. 
Interestingly, the standard deviation of 45° inclined hole measurements was notably 
greater than other orientations. Statistical analysis revealed no significant differences 
between any two pairs of horizontal holes. Vertical holes 2 and 4 were shown to be 
significantly different (p = 0.02). A number of pairs of individual inclined holes 
exhibited significantly different sizes and holes 2 and 3 were shown to be highly 
significantly different (p = 0.00). Overall, the size distribution of the horizontal hole 
measurements were shown to be vastly different from both the vertical and inclined 
channels (p < 0.001). 
 Figure 4: Microstructure of SLM implants a) 2D binary images of hole geometries (scale bars 
1 mm), b) 3D reconstruction of hole ROI, and c) measurements of hole size presented as 
mean ± standard deviation (n=4 for individual hole measurements and n=16 for all hole 
measurements). *p<0.05, **p<0.01, ***p<0.001 
Visualisation of the internal structure of SLM parts filled with gentamicin cement was 
achieved using micro-CT (Fig. 5). Coronal and axial slices through the middle of the 
implants revealed defects in the cement within all of the models, in particular for 
vertical pore geometries. Using CTVox software, greyscale values corresponding to 
the cement were segmented (Fig. 6 – 3D rendered cement volumes). Overall this 
demonstrated that the implants were filled with cement in the reservoir and the pore 
channels of all orientations. 
 
 
 
 
Figure 5: 3D visualisation of gentamicin loaded cement within demonstration implants (scale 
bars 2 mm) 
  
 As expected, the cumulative release of gentamicin from bare cement cylinders (≈ 
37%) was shown to be substantially greater than any of the SLM implants filled with 
antibiotic loaded cement (Fig. 6). Interestingly, despite each of the SLM part CAD 
models exhibiting the same surface pore area (four holes of 1 mm diameter), after 6 
h the total quantity of gentamicin released from implants with different channel 
orientations was notably different; vertical 28%, horizontal 10%, and inclined 5%. 
 
Figure 6: Cumulative release of gentamicin from brushite cement cylinders and cement filled 
implants. Result represented as mean ± standard deviation (n=3) 
 
The MIC of gentamicin against S. aureus and S. epidermis was found to be 16 and 1 
μg/mL, respectively. To confirm whether the concentrations of gentamicin released 
from samples (Fig. 6) were sufficient to inhibit the growth of S. aureus and S. 
epidermis an agar diffusion study was conducted ( Fig. 7). Near circular inhibition 
zones were observed for blank and gentamicin cement samples against S. aureus, 
and only for gentamicin loaded cement against S. epidermis ( Fig. 7b). Without 
gentamicin the cements did not inhibit the growth of S. epidermis.  
SLM parts were all shown to elute sufficient concentrations of gentamicin to inhibit 
the growth of both bacterial cultures (Fig. 7c). For all SLM designs irregularly shaped 
inhibition zones were observed. To reflect the irregular shape of the inhibition zones, 
the minimum and maximum diameters were approximated for each sample and the 
average calculated for each plate (n = 3, Fig. 7d and e). In some cases, samples 
with horizontal and inclined channels exhibited the maximum diameter of inhibition 
adjacent to where the channels were located. This led to more irregularly shaped 
inhibition zones; however, two-way paired t-tests conducted between minimum and 
maximum diameter measures only revealed statistical significance for implants with 
horizontally orientated pore channels (p = 0.05 S. aureus, p = 0.004 S. epidermis). 
Single factor ANOVA tests did not show any significance between the mean 
diameters for the three implant orientations for either bacterial species. Notably, 
areas of no growth for inclined and vertical SLM parts cultured with S. aureus and 
horizontal samples with S. epidermis were found to overlap; this made it difficult to 
determine the diameter of the zone contributed by individual samples.   
  
 
Figure 7: Agar plates after overnight culture of staph. aureus and staph. epidermis 
demonstrating a) sample layout; clear zones of bacterial inhibition on b) cement cylinders c) 
SLM parts; and d) minimum and maximum diameters of bacterial inhibition zones. Results 
presented as mean ± standard deviation (n=3) 
 
4. Discussion 
Set cements consist of three phases; product phase (brushite), residual reactant 
phase (β-TCP), and porosity. While both reactant and residual components 
contribute to stress resistance, porosity provides no support to the structure and so 
limits strength [32]. It is also important to note the inverse relationship between the 
largest pore size and critical tensile strength, as noted by Griffith [33]. A number of 
other factors are known to influence cement strength, including the degree of 
residual product, which may act as an aggregate and positively impact stress 
resistance if it is of a higher density [34] and [35]. Compared with cast samples, the 
average compressive strength was shown to improve as a result of injection and 
addition of gentamicin to the liquid phase, i.e. σcast ≈ σinjected < σinjected 
gentamicin (Table 1). This trend correlates with an increase in aggregate phase 
quantity, i.e. residual β-TCP content (Fig. 3). Since the microstructure of cast and 
injected samples without gentamicin was not obviously different it may be assumed 
that the positive influence of residual β-TCP dominates the effect of porosity changes 
for these samples. Interestingly, Bohner et al. noted an improvement in tensile 
strength of brushite cements as a result of gentamicin addition [36]. This was 
ascribed to the decrease in size and thickness of DCPD particles due to the 
presence of sulphate ions in gentamicin (35 ± 2%). A similar morphological change 
was observed between injected samples with and without gentamicin (Fig. 2b). 
Therefore the strength improvement as a result of gentamicin incorporation may be 
attributed to a compounding effect of a greater amount of residual β-TCP and a finer 
microstructure. For this study, compressive strength was determined at one time 
point. The trends observed may be expected to vary as a result of different profiles of 
antibiotic elution and material dissolution. It may be interesting to explore the time 
dependent relationships of mechanical properties in future work. However, if the 
cement is housed within a metallic component its strength would contribute negligibly 
to the total and therefore would not require optimisation. 
 
The average values of porosity measured using helium pycnometer (Table 1) and 
micro-CT (Fig. 4) for injected cement samples were within one standard deviation of 
each other. For cast samples, however, the porosity value calculated from micro-CT 
analysis (17.9%) was significantly outside the average calculated from helium 
pycnometer measurements (25.6 ± 1.2%). The detection levels achievable via micro-
CT (1–2 μm) are far larger than those for helium pycnometer (2–50 nm). There are 
three types of porosity presence in set cements; gel (intrinsic to the structure), 
capillary (formed via evaporation of excess water), and macroporosity. Since the 
typical sizes of both gel (0.5–10 nm) and capillary (5 nm–5 μm) pores fall largely 
outside the limit of micro-CT, differences in porosity values obtained using these two 
modalities are only to be expected. The use of micro-CT enabled open and closed 
porosity to be distinguished, visualised, and quantified (Fig. 3 and Table 2). This 
revealed that gentamicin loaded cements exhibited a smaller volume fraction of open 
and closed pores > 24.4 μm compared with other samples. The compressive 
strength of brittle materials will be related closely to the size of the defect 
encountered in the maximum stress field from which the fracture originates. A clear 
reduction in the frequency of larger defects was shown in gentamicin loaded 
samples (Table 2), which suggests why this formulation exhibited a significantly 
higher compressive strength (Table 1). 
 
Micro-CT was used to probe the internal structure of SLM parts and revealed minor 
defects within all of the structures (Fig. 4a). In particular, the degree of porosity seen 
in binary coronal slices of inclined parts can be seen to be greater in the uppermost 
layers. During SLM the depth of laser penetration may be greater than the thickness 
of one layer. As such the layers built first may be consolidated to a greater extent as 
they are passed over by the laser more times than those layers at the top of the 
build. The observed honey-comb like microstructure (Fig. 4a – inclined part near to 2 
mm diameter hole) and the rough internal surface topography of the holes (Fig. 4b) 
are commonly observed with partial powder melting, which occurs if the energy input 
is insufficient to induce significant melting of the powder particles. Song et al. 
demonstrated that laser power and scanning speed strongly effect the processing 
mechanism (melting with cracks, continuous melting, and partial melting), which in 
turn affects surface topology, part density, and micro-hardness [37]. The inherent 
micro-roughness of SLM parts may be advantageous to cell adhesion and 
differentiation [38], however, this surface topography is known to limit fatigue 
performance [26]. Optimisation of manufacturing and post-processing parameters 
(e.g. polishing) will be critical to manufacturing implants that have sufficient 
mechanical properties and exhibit surfaces that facilitate cellular adhesion but limit 
bacterial adhesion. In future studies, particularly those concerning long-term 
implants, it will be important to assess whether the addition of pore channels to the 
structure facilitates biofilm development. 
 
Computed tomographic 3D rendering of implant models filled with gentamicin-loaded 
cements revealed macroscopic porosity within all designs (Fig. 5 coronal slice). The 
majority of these defects were observed at the top of the designs where the internal 
architecture of the manufactured part forms a right angle. In casting, this type of 
defect is often called back-pressure porosity and is caused by inability of the air in 
the mould to escape or by the pressure gradient that displaces air pockets towards 
the end of the mould [39]. It is therefore suggested that future designs should have 
curved internal surfaces to minimise back-pressure porosity formation. Furthermore, 
it appears that a greater volume of air remains in the structure when the pores are 
orientated parallel to the direction of injection, i.e. vertical, since this was the only 
sample where defects were visualised in the axial slice (Fig. 5). This orientation of 
pores is likely to have a lower backpressure compared with pores located on the side 
of the implant as such it appears less entrapped air is forced out of the reservoir. 
Baroud et al. concluded that high cement viscosity is required to stabilise cement 
flow in vertebroplasty; however, this was shown to negatively impact the injectability 
and working time of the formulation [40]. In future work it may be interesting to 
assess any trade-off between increasing the viscosity of the cement system, for 
example by increasing the powder to liquid ratio, and the ability of the cement to fully 
fill the implant. Alternatively, vibration could be used to expel air bubbles from the 
implant, although this would only be viable if the cavity were filled before 
implantation. The surface finish of the internal reservoir may also be expected to 
influence the flow of the injected material. Inherently, SLM parts exhibit a rough 
surface topography, as demonstrated in micro-CT images (Fig. 4 and Fig. 5), 
therefore it is suggested that optimisation of surface finishing methods, such as 
tumbling and polishing, may also be required. 
 
Diffusion occurs as a result of a concentration gradient, which is a difference in the 
concentration of diffusion species between two separated positions. For elution of 
the antibiotic to occur, the solvent (PBS), would have to infiltrate the cement porosity. 
The entirety of the cement cylinder surface area (approximately 680 mm2) was 
exposed to the surrounding media and in comparison the pore channels and 
injection hole total an estimated 25mm2. Therefore, the greater percentage of the 
gentamicin released from cement cylinders (≈ 37%) compared to the implant models 
(< 28%) is to be expected since the larger available surface area of the cylinder 
allows for faster infiltration of the cement porosity with PBS (Fig. 6). Interestingly, the 
release profile of gentamicin from the implant with vertically-orientated pore channels 
was obviously different to the horizontal and inclined samples. Since all four pore 
channels in the vertical design are located on one face of the model (Fig. 1), i.e. they 
are closer together compared with the other designs, it is probable that local 
infiltration of the cement with PBS would occur more quickly and as a result diffusion 
of the antibiotic would have been initiated earlier. In comparison, the pore channels 
for the horizontal and inclined implant designs were located in pairs on opposite 
sides of the cylinder (Fig. 1). The local pore surface area available for PBS infiltration 
was therefore half that of the vertical design, which may have influenced the rate and 
degree of cement infiltration and ultimately reduced the concentration gradient. This 
local change in the number of pores on each face may explain why a higher 
concentration of gentamicin from the vertical pores (21 mg, 28% of the total 
concentration incorporated in the cement) was detected within the 6 h period 
compared with horizontal (7.4 mg, 10%) and inclined (3.9 mg, 5%) samples. 
Regardless, the concentrations of gentamicin released throughout the 6 hour period 
exceeded the MIC for both S. aureus (16 μg/mL) and S. epidermidis (1 μg/mL), 
which was consistent with the results of the agar diffusion study (Fig. 7). Future 
work, which will involve the design of clinically specific implants, will require a longer 
term release study to be conducted; the time frame of this study will be matched to 
the desired antibiotic delivery for the chosen clinical application. Typically when an 
infected implant is removed antibiotics are administered intravenously for 2–8 weeks 
[41]. Therefore it may be necessary to extend the period in which the antibiotic is 
released from the implant reservoir. To achieve this, polymeric microspheres may be 
used to encapsulate the antibiotic, which may be incorporated into the cement [42] 
and [43]. 
 
Cement cylinders without gentamicin were shown to exhibit some ability to inhibit the 
growth of S. aureus but had limited effect against S. epidermidis ( Fig. 7b). This 
efficacy may be attributed to the acidity of the cement. The addition of gentamicin 
into the cement was clearly shown to increase the inhibitory zone for both 
investigated cultures. Statistical analysis demonstrated a significant difference 
between the minimum and maximum inhibition diameters for horizontal pore 
channels against both bacteria (Fig. 7d and e). Therefore this orientation may not be 
preferable to ensure a symmetrical release zone. However, no significant difference 
was demonstrated between any measurements (i.e. minimum and maximum 
diameters) for each of the three orientations. Generally, this assay demonstrated the 
importance of considering the number and location of pores required to ensure that 
all cultures are eradicated. Optimisation of this inhibition in 3-dimensions will be 
required to translate this concept to the clinic; however introduction of further pore 
channels will need to be traded off against any impact on mechanical integrity. 
 
Overall, we have demonstrated that there is further added value to be gained by full 
utilisation of the geometrical freedom made possible by AM. Promisingly, we have 
shown the ability to use such a strategy to manufacture a structure that eludes 
clinically-relevant concentrations of antibiotic. Interestingly, the back-pressure 
porosity observed within the cement cavity (Fig. 5) raises the question as to whether 
such an implant should be filled prior to implantation or in-situ. The former would 
facilitate the use of methods, such as vibration, to minimise any defects within the 
injected material. This option may be preferable so as not to increase operating 
times and to ensure greater reproducibility. Alternatively, in some instances (e.g. a 
screw) overfilling of the implant once it is implanted may provide some additional 
torsional stability. Future development of this technology will require mechanical 
optimisation of the implant design for the intended clinical application. Introduction of 
a lattice structure, such as that illustrated in Fig. 1b, within the designed cavity region 
may be required to match the implant mechanical properties to the surrounding 
tissue. This would avoid stress risers that can predispose to mechanical failure. 
 
This work is a proof of concept demonstration of the potential of AM to allow novel 
geometries in orthopaedic implants. There are, however, several specific clinical 
applications that may benefit from an orthopaedic implant capable of providing both 
structural support and the potential for long-term release of a drug from a reservoir. 
The first is in two-stage revisions for infected arthroplasty. One problem with this 
process is that the mechanical properties of antibiotic-loaded PMMA spacer are not 
suitable for significant weight-bearing and thus patients' mobility is severely 
compromised during this time. If an AM implant containing an antibiotic-eluting 
reservoir was used instead (such as illustrated in Fig. 1b), then the patients would be 
better able to weight-bear in the interim period with the benefits of greater 
independence, reduced loss of cardiovascular and musculoskeletal condition, and 
reduced pain. Other significant problems with the standard methodology are that the 
choice and dose of antibiotic suitable for loading into PMMA spacers are limited. The 
ability to use a wider range or even mixture of antibiotics in the implant would allow 
more specificity in treatment. The ability to increase the dose available for elution 
could increase the duration of treatment. These advantages would be particularly 
useful in an era of ever-increasing antibiotic resistance. The second clinical 
application of such a technology could be in orthopaedic tumour surgery. Tumour 
excision is often followed by implantation of prostheses to maintain mechanical 
function. If such prostheses could contain a reservoir of a chemotherapeutic agent to 
be eluted into the site of tumour excision then it may be possible to reduce the 
incidence of local recurrence. The ease with which AM can be used to produce 
bespoke prostheses would be of particular advantage in this application given that 
bone tumours may occur in such a wide variety of anatomical locations. Finally, 
manufacturing an intramedullary nail with the capability of delivering osteogenic 
factors or even osteoblasts to the fracture site may confer clinical benefit, either in 
primary surgery or as a treatment for fracture non-union. 
5. Conclusions  
Cylindrical Ti-6Al-4V implants incorporating a surface connected reservoir region 
were successfully manufactured via SLM and filled with gentamicin loaded brushite 
cement. Implant surfaces were shown to exhibit micro-roughness, which will require 
further investigation to assess any trade-off between cellular attachment and 
bacterial adhesion as well as fatigue performance. Interestingly, pore channels built 
parallel to the build bed, i.e. horizontal, were shown to exhibit less size variability 
than vertically or inclined pore orientations. This observation will be taken into 
account as the concept is progressed towards clinical use. 
Micro-CT revealed the presence of microscopic defects within cement injected into 
implants of all pore orientations. However, this was observed to be more pronounced 
when the flow of cement was parallel to the orientation of pore channels (i.e. 
vertical), which was attributed to a lower back-pressure dispelling less entrapped air. 
Due to the presence of back-pressure porosity within all implant designs it is 
suggested that it may be optimal to fill such implants prior to implantation in a 
controlled environment to improve reproducibility and not prolong operation times. 
Incorporation of the antibiotic cement within the implant models was shown to control 
the release compared with a blank cement cylinder. Over 6 h the concentration of 
gentamicin released from all orientations of pore channel exceeded the MIC of both 
S. aureus and S. epidermidis. The assertion made from the release study was 
confirmed by demonstrating zones of bacterial inhibition using an agar diffusion 
assay. Interestingly, some directionality of antibiotic release was observed for the 
horizontal and inclined pore channel implants. Overall, this study highlights that there 
is still much potential to further utilise AM in healthcare technologies to add new 
implant functionality.    
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